Clinical trials: Metastasis to Liver
Liver Metastasis Colon Cancer
LT for Unresectable Colorectal Liver Metastasis
Unlike hepatocellular carcinoma, liver transplantation in patients with liver metastasis from colorectal cancer is limited in only few centers.
- Trial name
- NCT04874259
- Testing
- Living donor liver transplantation
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma, Metastatic Cancer
GEN2 Directed Cancer Immunotherapy Trial
Phase 1, non-randomized, open label dose escalation clinical trial evaluating the safety of GEN2 in participants with primary \& metastatic liver tumors.
- Trial name
- GEN2 (NCT04313868)
- Testing
- GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
- Where
- 4 sites in Philippines
- Volunteers
- 61 people
- Sponsor
- GenVivo, Inc.
Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis
A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread
This is an open-label, single-arm, prospective, multicenter clinical study designed to evaluate the efficacy and safety of envafolimab in combination with lenvatinib for the treatment of patients with clear cell renal cell…
- Trial name
- NCT07256223
- Testing
- Envafolimab+Lenvatinib
- Volunteers
- 30 people
- Sponsor
- Fudan University
Liver Cancer
Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome
The purpose of this study is to see if the investigators can do some tests on tissue from the area of the ablation. The investigators want to know if a test can help predict whether the ablation worked.
- Trial name
- NCT01494324
- Testing
- CT guided percutaneous ablation
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer With Liver Metastases
A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG002 in patients with HER2 positive breast cancer with liver metastases.
- Trial name
- NCT05263869
- Testing
- MRG002
- Where
- 2 sites in China
- Volunteers
- 99 people
- Sponsor
- Shanghai Miracogen Inc.
Metastatic Colorectal Cancer
HepaSphere™ Microspheres Prospective Registry
HepaSphere™ Microspheres loaded with irinotecan received CE mark for the indication of use in embolization of metastatic colorectal cancer (mCRC) to the liver in 2015.
- Trial name
- mCRC (NCT04866290)
- Testing
- HepaSphere Microspheres
- Where
- 2 sites in France, Greece
- Volunteers
- 105 people
- Sponsor
- Merit Medical Systems, Inc.
Histologically Confirmed Metastatic or Locally Advanced Breast Cancer With no Radical Topical Treatment Available, If There is Liver Metastasis, Which the Researcher Believes Will be Difficult to Evaluate the Response Accurately With Bone Metastasis or CT
FDG PET-CT in Advanced Breast Cancer
This study is a prospective cohort study comparing metabolic response evaluation by F-18 FDG PET-CT versus conventional imaging for outcome stratification in patients with advanced breast cancer receiving first-line systemic…
- Trial name
- PET-000 (NCT07173868)
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Colorectal Cancer, Unresectable Liver Metastasis
Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis
An innovative therapeutic strategy to increase the complete resection rate is of utmost importance in order to enhance survival in colorectal cancer patients with unresectable liver-only metastasis.
- Trial name
- NCT00743678
- Testing
- FOLFOX6/cetuximab
- Where
- South Korea
- Volunteers
- 73 people
- Sponsor
- Samsung Medical Center
Colon Cancer Liver Metastasis
Observational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab
The recently introduced chemoembolization has been considered to be a very attractive new method in terms of response in the treatment of liver metastases from colon cancer carcinoma (LM-CRC).
- Trial name
- TACETUX (NCT01891552)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- International Group of Endovascular Oncology
Liver Metastases, Colorectal Cancer
Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer
The role of radiotherapy in metastatic cancer has historically been limited to palliation while metastasectomy or radiofrequency has emerged as playing a major role in disease control.
- Trial name
- OLIVER (NCT03532204)
- Testing
- SBRT, Chemotherapy
- Sponsor
- UNICANCER
Neoplasm Metastasis
Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases
This study aims to prove that a strategy of first line local ablation of colorectal liver metastases with microwaves is not inferior to liver resections in terms of survival rates at three years with secondary endpoints being…
- Trial name
- MAVERRIC (NCT02642185)
- Testing
- Microwave ablation, Resection
- Where
- 3 sites in Netherlands, Sweden and 1 more
- Volunteers
- 102 people
- Sponsor
- Karolinska Institutet
Liver Cancer
Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases
Up to twenty-two patients will be enrolled in this study to receive autologous dendritic cells (DCs) administered intratumorally into liver metastases following radiofrequency thermal ablation of those lesions.
- Trial name
- NCT00185874
- Testing
- Intratumoral Dendritic Cell Immunotherapy, autologous dendritic cells
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Metastatic Uveal Melanoma in the Liver
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
This study is an open-label, phase 1/1b study of the pressure-enabled hepatic artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma.
- Trial name
- NCT04935229
- Testing
- SD-101, Nivolumab, Ipilimumab
- Where
- 10 sites in United States
- Volunteers
- 67 people
- Sponsor
- TriSalus Life Sciences, Inc.
PDAC - Pancreatic Ductal Adenocarcinoma
Forecasting Occult liveR Metastasis Using an Exosomal Signature for Intelligent Guided Hepatic Targeting
Early liver metastasis (Early-LiM) is the most significant prognostic factor in pancreatic ductal adenocarcinoma (PDAC) and is thought to originate from occult micrometastases present at the time of surgery.
- Trial name
- FORESIGHT (NCT07224802)
- Testing
- EXELiM assay (qRT-PCR validation), EXELiM small RNA sequencing
- Where
- United States
- Volunteers
- 372 people
- Sponsor
- City of Hope Medical Center
Carcinoma, Hepatocellular
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic…
- Trial name
- NCT04246177
- Testing
- Lenvatinib, Pembrolizumab, TACE
- Where
- 205 sites in United States, Australia and 25 more
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Metastases, Breast Cancer
Radioembolisation and Chemotherapy in Liver Metastatic Breast Cancer Patients
The goal of this multicentre clinical pilot study is to investigate the feasibility of the addition of Ho-166 radioembolization to chemotherapy in patients with liver metastastic breast cancer.
- Trial name
- HoLiBreast (NCT06142344)
- Testing
- Quiremspheres™
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 13 people
- Sponsor
- The Netherlands Cancer Institute
Liver Metastases, Non-small Cell Lung Cancer
Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.
- Trial name
- NCT05430009
- Testing
- Liver SBRT, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Ann Arbor Healthcare System
Solid Tumor, Adult, Solid Tumor
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
This clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06075849
- Testing
- PB101
- Where
- 3 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Panolos Bioscience
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread…
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
- Trial name
- NCT05863195
- Testing
- Bevacizumab, Capecitabine, Cetuximab
- Where
- 62 sites in United States
- Volunteers
- 408 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
GIST, Malignant, Liver Metastases
Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM
The goal of this observational study is to evaluate the overall survival benefits of local treatment combined with imatinib(IM) and IM alone in patients suffering from GIST liver metastases.
- Trial name
- NCT06038552
- Testing
- imatinib (IM), hepatic resection (HR), radiofrequency ablation (RFA)
- Where
- China
- Volunteers
- 238 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.